ImaBiotechs Multimaging Technology Chosen by Dermira for Its Skin Disposition Study
Summary
The highest strength DRM01 gel (7.5%) demonstrated the deepest level of penetration into the dermis, the area of the skin where the sebaceous glands are located, suggesting a dose response.“We were excited to share the results of this skin disposition animal study of our DRM01 topical anti-acne product candidate at the ESDR Meeting,” said Hans Hofland, Ph.D., vice president, research at Dermira.In order to accelerate drug development, ImaBiotech offers Mass Spectrometry Services to provide a cost effective solution to preclinical and clinical studies.Lille, France, December 07, 2015 --( PR.com )-- ImaBiotech today announced that Dermira, Inc., a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, chose ImaBiotech’s Multimaging technology for a skin disposition study in Yorkshire pigs.In order to accelerate drug development, ImaBiotech offers Mass Spectrometry Services to provide a cost effective solution to preclinical and clinical studies.